powered by StockChartsAI.com

All Charts and Prices Based on Previous Days Close

Enter Stock Symbol to View AI powered Stock Chart

By accessing this site, you agree we are not liable, whether in contract, tort (including negligence) or otherwise, in respect of any damage, expense or other loss you may suffer arising out of such information or any reliance you may place upon such information from this site.

Organon & Co (OGN)

Industry: Drug Manufacturers - General

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.

Organon & Co Website


Institution %: 79.679

YTD Institution change: 10223984


Insiders %: 0.101

Insiders Purchases YTD: 2720

Insiders Sales YTD:

Insiders Net YTD: 2720

Analyst Ratings

Target Price: 29.29

Overall Rating: 3.3333

Strong Buys (5): 1

Buys (4): 3

Holds (3): 3

Sells (2): 2

Strong Sells (1): 0


52 Week Hi: 23.5605

52 Week Low: 10.6714

Beta: 0.758

50 Day MA: 15.7618

200 Day MA: 17.6995

Earnings / Revenue Trends

Qtr Earnings Growth YOY: 4.065

Qtr Revenue Growth YOY: 0.076

Forward PE:

Trailing PE: